Innovate: New Horizons
On Friday, the New Horizons Forum, a full day of presentations, panels, and discussions featuring leaders from start-up companies, industry executives, ophthalmic experts, venture capitalists, and the FDA, will be held.
Adrienne Graves, PhD, co-founder and co-chair of Glaucoma 360, said that putting all these innovators, experts, and investors in the same room helps bring ideas to fruition more quickly than might otherwise be possible
“We are committed to putting new technologies and groundbreaking research in front of audiences that can help turn the ideas into new glaucoma products,” Dr. Graves said.
She said it has been gratifying to see technologies that were presented at New Horizons receive additional funding, with a number of them acquired by strategics and/or brought to market.
“We have witnessed some of these connections taking place, and that is rewarding,” Dr. Graves said.
She also noted one of the most valuable aspects of this meeting is the opportunity it gives to highlight the latest glaucoma advances.
“It is never the same meeting twice,” she said. “The field has seen an enormous proliferation of new surgical devices, new drug delivery systems, and new drug candidates. We are excited to showcase these advances to our attendees.”
One focus of this year’s forum will be the use of virtual reality in glaucoma care, with presentations on research and product development.
The Opening Keynote Address will be given by Ike Ahmed, MD, FRCSC, medical director, Prism Eye Institute; associate professor of ophthalmology, University of Toronto; and clinical professor of ophthalmology, University of Utah. His topic will be “Interventional Glaucoma: The Why, The Who, and The How.”
Registration for New Horizons is $495 for physicians until Dec. 15 and $595 after that date.